Using anti-PD-L1 antibody conjugated gold nanoshelled poly (Lactic-co-glycolic acid) nanocapsules loaded with doxorubicin: A theranostic agent for ultrasound imaging and photothermal/chemo combination therapy of triple negative breast cancer.

Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101234237 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4965 (Electronic) Linking ISSN: 15493296 NLM ISO Abbreviation: J Biomed Mater Res A Subsets: MEDLINE

Original Publication: Hoboken, NJ : John Wiley & Sons, c2002-

Nanocapsules*/chemistry ; Triple Negative Breast Neoplasms*/diagnostic imaging ; Triple Negative Breast Neoplasms*/drug therapy ; Nanoparticles*/chemistry ; Glycolates*; Humans ; Glycols ; Precision Medicine ; Gold/chemistry ; B7-H1 Antigen ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Ultrasonography/methods ; Cell Line, Tumor

Triple negative breast cancer (TNBC) has the worst prognosis of all breast cancers, and it is difficult to progress through traditional chemotherapy. Therefore, the treatment of TNBC urgently requires agents with effective diagnostic and therapeutic capabilities. In this study, we obtained programmed death-ligand 1 (PD-L1) antibody conjugated gold nanoshelled poly(lactic-co-glycolic acid) (PLGA) nanocapsules (NCs) encapsulating doxorubicin (DOX) (DOX@PLGA@Au-PD-L1 NCs). PLGA NCs encapsulating DOX were prepared by a modified single-emulsion oil-in-water (O/W) solvent evaporation method, and gold nanoshells were formed on the surface by gold seed growth method, which were coupled with PD-L1 antibodies by carbodiimide method. The fabricated DOX@PLGA@Au-PD-L1 NCs exhibited promising contrast enhancement in vitro ultrasound imaging. Furthermore, DOX encapsulated in NCs displayed good pH-responsive and photo-triggered drug release properties. After irradiating 200 μg/mL NCs solution with a laser for 10 min, the solution temperature increased by nearly 23°C, indicating that the NCs had good photothermal conversion ability. The targeting experiments confirmed that the NCs had specific target binding ability to TNBC cells overexpressing PD-L1 molecules. Cell experiments exhibited that the agent significantly reduced the survival rate of TNBC cells through photochemotherapy combination therapy. As a multifunctional diagnostic agent, DOX@PLGA@Au-PD-L1 NCs could be used for ultrasound targeted contrast imaging and photochemotherapy combination therapy of TNBC cells, providing a promising idea for early diagnosis and treatment of TNBC.
(© 2023 Wiley Periodicals LLC.)

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247-269.
Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110-122.
Aydinlik S, Erkisa M, Cevatemre B, et al. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line. Biochim Biophys Acta Gen Subj. 2017;1861(2):49-57.
Alkaraki A, Alshaer W, Wehaibi S, et al. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes. Breast Cancer. 2020;27(5):989-998.
Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (review). Int J Oncol. 2020;57(6):1245-1261.
Nakhjavani M, Samarasinghe RM, Shigdar S. Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options. Drug Discov Today. 2022;27(5):1298-1314.
Ma Q, Sun X, Wang W, et al. Diketopyrrolopyrrole-derived organic small molecular dyes for tumor phototheranostics. Chin Chem Lett. 2022;33(4):1681-1692.
Dai H, Cheng Z, Zhang T, et al. Boron difluoride formazanate dye for high-efficiency NIR-II fluorescence imaging-guided cancer photothermal therapy. Chin Chem Lett. 2022;33(5):2501-2506.
Feng G, Zhang GQ, Ding D. Design of superior phototheranostic agents guided by Jablonski diagrams. Chem Soc Rev. 2020;49(22):8179-8234.
Du C, Qian J, Zhou L, Su Y, Zhang R, Dong CM. Biopolymer-drug conjugate Nanotheranostics for multimodal imaging-guided synergistic cancer photothermal-chemotherapy. ACS Appl Mater Interfaces. 2017;9(37):31576-31588.
Peng C, Chen M, Spicer JB, Jiang X. Acoustics at the nanoscale (nanoacoustics): a comprehensive literature review: part II: nanoacoustics for biomedical imaging and therapy. Sens Actuators A Phys. 2021;332(Pt 2):112925.
El-Hammadi MM, Arias JL. Recent advances in the surface functionalization of PLGA-based nanomedicines. Nanomaterials. 2022;12(3):354.
Li L, Fu J, Wang X, et al. Biomimetic "nanoplatelets" as a targeted drug delivery platform for breast cancer Theranostics. ACS Appl Mater Interfaces. 2021;13(3):3605-3621.
Dong Q, Wan C, Yang H, et al. Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer. J Biomater Appl. 2020;35(3):430-445.
Onaciu ABC, Zimta AA, et al. Gold nanorods: from anisotropy to opportunity. An evolution update. Nanomedicine. 2019;14(19):1203-1226.
Ke H, Yue X, Wang J, et al. Gold nanoshelled liquid perfluorocarbon nanocapsules for combined dual modal ultrasound/CT imaging and photothermal therapy of cancer. Small. 2014;10(6):1220-1227.
Gupta N, Malviya R. Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188532.
Emami F, Banstola A, Vatanara A, et al. Doxorubicin and anti-PD-L1 antibody conjugated gold nanoparticles for colorectal cancer photochemotherapy. Mol Pharm. 2019;16(3):1184-1199.
Zeng F, Du M, Chen Z. Nanosized contrast agents in ultrasound molecular imaging. Front Bioeng Biotechnol. 2021;9:758084.
Núñez Abad M, Calabuig-Fariñas S, Lobo de Mena M, et al. Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer. Cancers. 2022;14(2):307.
Hudson K, Cross N, Jordan-Mahy N, Leyland R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020;11:568931.
Zhang J, Tian Q, Zhang M, Wang H, Wu L, Yang J. Immune-related biomarkers in triple-negative breast cancer. Breast Cancer. 2021;28(4):792-805.
Chen C, Li S, Xue J, et al. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight. 2021;6(8):e131458.
Xu L, Wan C, Du J, et al. Synthesis, characterization, andin vitroevaluation of targeted gold nanoshelled poly(d,l-lactide-co-glycolide) nanoparticles carrying anti p53 antibody as a theranostic agent for ultrasound contrast imaging and photothermal therapy. J Biomater Sci Polym Ed. 2017;28(4):415-430.
Ke H, Wang J, Dai Z, et al. Gold-nanoshelled microcapsules: a theranostic agent for ultrasound contrast imaging and photothermal therapy. Angew Chem Int Ed Engl. 2011;50(13):3017-3021.
Hao Y, Zhang B, Zheng C, et al. The tumor-targeting core-shell structured DTX-loaded PLGA@Au nanoparticles for chemo-photothermal therapy and X-ray imaging. J Control Release. 2015;220:545-555.
Ding D, Zhu Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater Sci Eng C Mater Biol Appl. 2018;92:1041-1060.
Liu G, McEnnis K. Glass transition temperature of PLGA particles and the influence on drug delivery applications. Polymers. 2022;14(5):993.
Rastinehad AR, Anastos H, Wajswol E, et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc Natl Acad Sci USA. 2019;116(37):18590-18596.
Tian Y, Qiang S, Wang L. Gold nanomaterials for imaging-guided near-infrared in vivo cancer therapy. Front Bioeng Biotechnol. 2019;7:398.
Zhu A, Miao K, Deng Y, et al. Dually pH/reduction-responsive vesicles for ultrahigh-contrast fluorescence imaging and thermo-chemotherapy-synergized tumor ablation. ACS Nano. 2015;9(8):7874-7885.
Yang R, An J, Zhu H, Yan X, Gao H. Multipronged design of theranostic nanovehicles with endogenous and exogenous stimuli-responsiveness for precise cancer therapy. J Mater Chem B. 2019;7(7):1160-1166.
Cheng Y, Bao D, Chen X, et al. Microwave-triggered/HSP-targeted gold nano-system for triple-negative breast cancer photothermal therapy. Int J Pharm. 2021;593:120162.
Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE. 2014;9:e88557.
Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.
Lin HC, Hsu KF, Lai CL, Wu TC, Chen HF, Lai CH. Mannoside-modified branched gold nanoparticles for photothermal therapy to MDA-MB-231 cells. Molecules. 2020;25(8):1853.
Lv Z, He S, Wang Y, Zhu X. Noble metal nanomaterials for NIR-triggered photothermal therapy in cancer. Adv Healthc Mater. 2021;10(6):e2001806.
Li Z, Chen Y, Yang Y, et al. Recent advances in nanomaterials-based chemo-photothermal combination therapy for improving cancer treatment. Front Bioeng Biotechnol. 2019;7:293.
Qi Y, Zhang L, Wang Z, et al. Efficacy and safety of anti-PD-1/ PD-L1 monotherapy for metastatic breast cancer: clinical evidence. Front Pharmacol. 2021;12:653521.
Shen Y, Lv W, Yang H, et al. FA-NBs-IR780: novel multifunctional nanobubbles as molecule-targeted ultrasound contrast agents for accurate diagnosis and photothermal therapy of cancer. Cancer Lett. 2019;455:14-25.
Jing L, Liang X, Li X, et al. Mn-porphyrin conjugated Au nanoshells encapsulating doxorubicin for potential magnetic resonance imaging and light triggered synergistic therapy of cancer. Theranostics. 2014;4(9):858-871.
Zheng D, Wan C, Yang H, et al. Her2-targeted multifunctional Nano-Theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment. Int J Nanomedicine. 2020;15:10007-10028.
Topete A, Alatorre-Meda M, Villar-Alvarez EM, et al. Polymeric-gold nanohybrids for combined imaging and cancer therapy. Adv Healthc Mater. 2014;3(8):1309-1325.
Mosafer J, Teymouri M. Comparative study of superparamagnetic iron oxide/doxorubicin co-loaded poly (lactic-co-glycolic acid) nanospheres prepared by different emulsion solvent evaporation methods. Artif Cells Nanomed Biotechnol. 2018;46(6):1146-1155.
Banstola A, Poudel K, Emami F, et al. Localized therapy using anti-PD-L1 anchored and NIR-responsive hollow gold nanoshell (HGNS) loaded with doxorubicin (DOX) for the treatment of locally advanced melanoma. Nanomedicine. 2021;33:102349.
Wang CW, Yang SP, Hu H, Du J, Li FH. Synthesis, characterization and in vitro and in vivo investigation of C(3)F(8)-filled poly(lactic-co-glycolic acid) nanoparticles as an ultrasound contrast agent. Mol Med Rep. 2015;11(3):1885-1890.
Persi E, Duran-Frigola M, Damaghi M, et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun. 2018;9(1):2997.
Cui X, Liang Z, Lu J, et al. A multifunctional nanodiamond-based nanoplatform for the enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer via an autophagy regulation strategy. Nanoscale. 2021;13(31):13375-13389.

82071954 National Natural Science Foundation of China; 81102014 National Natural Science Foundation of China; PW2019D-6 The Joint Research Project of Health and Family Planning of Shanghai Pudong New Area Health Committee

Keywords: anti-PD-L1 antibody; gold nanoparticles; photochemotherapy; triple negative breast cancer; ultrasound imaging

0 (Nanocapsules)
0 (Glycols)
7440-57-5 (Gold)
0 (B7-H1 Antigen)
0WT12SX38S (glycolic acid)
80168379AG (Doxorubicin)
0 (Glycolates)

Date Created: 20231109 Date Completed: 20240122 Latest Revision: 20240415

20240415

10.1002/jbm.a.37638

37941485